Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib versus investigator's choice of idelalisib + rituximab or bendamustine + rituximab in relapsed or refractory chronic lymphocytic leukemia
MOH_2017-03-19_000255Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Acerta Pharma. Started Oct 2016; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-03-19_000255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-19_000255.